Background-The high prevalence of obstructive sleep apnoea (OSA) in patients with systemic hypertension and of hypertension in patients with OSA suggests a causal link between the two disorders. This study was carried out to determine whether nasal continuous positive airway pressure (CPAP) and weight loss affect daytime hypertension in OSA. Methods-Sixty hypertensive patients with OSA took part in the study; 33 accepted nasal CPAP and used their machine for 5 7 (0.2) hours per night, and the remaining 27 patients refused nasal CPAP and upper airway surgery so the only therapeutic intervention was a recommendation of weight loss. A significant change in hypertension during follow up was defined as either a change in mean blood pressure of at least 10 mm Hg (or more than 8%) without a change in drug treatment, or a reduction in drug dosage with mean blood pressure within these limits. Weight loss was defined as a body mass index of at least 5% below the baseline value. Results-After 512 (41) days, hypertension had become less severe in seven of 12 patients (58%) treated with weight loss only, in eight of 28 patients (29%) with nasal CPAP only, in two of five patients with nasal CPAP and weight loss, and in one of 15 patients without nasal CPAP or weight loss. Multivariate analysis of variance with the outcome of hypertension at follow up as the dependent variable revealed that only the percentage change in body mass index significantly contributed to the course of hypertension. Conclusion-The course of hypertension in OSA is more closely linked to weight loss than to elimination of sleep apnoea by nasal CPAP.
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Background-The high prevalence of obstructive sleep apnoea (OSA) in patients with systemic hypertension and of hypertension in patients with OSA suggests a causal link between the two disorders. This study was carried out to determine whether nasal continuous positive airway pressure (CPAP) and weight loss affect daytime hypertension in OSA. Methods-Sixty hypertensive patients with OSA took part in the study; 33 accepted nasal CPAP and used their machine for 5 7 (0.2) hours per night, and the remaining 27 patients refused nasal CPAP and upper airway surgery so the only therapeutic intervention was a recommendation of weight loss. A significant change in hypertension during follow up was defined as either a change in mean blood pressure of at least 10 mm Hg (or more than 8%) without a change in drug treatment, or a reduction in drug dosage with mean blood pressure within these limits. Weight loss was defined as a body mass index of at least 5% below the baseline value. Results-After 512 (41) days, hypertension had become less severe in seven of 12 patients (58%) treated with weight loss only, in eight of 28 patients (29%) with nasal CPAP only, in two of five patients with nasal CPAP and weight loss, and in one of 15 patients without nasal CPAP or weight loss. Multivariate analysis of variance with the outcome of hypertension at follow up as the dependent variable revealed that only the percentage change in body mass index significantly contributed to the course of hypertension. Conclusion-The course of hypertension in OSA is more closely linked to weight loss than to elimination of sleep apnoea by nasal CPAP. (Thorax 1993; 48:529-533) Systemic hypertension is associated with male gender, age and obesity.' 2 As obstructive sleep apnoea (OSA) predominantly occurs in overweight, middle aged men,3 a close association between hypertension and OSA is not surprising. Extraordinarily high prevalences of hypertension in patients with OSA have been reported, however,67 and an elevated apnoea index has been found in up to 48% of unselected hypertensive patients,8-'" so that a causal link between OSA and hypertension has been suggested. The hypothesis that OSA causes hypertension is favoured by reports of blood pressure returning to normal levels after treatment for OSA. '2-14 If a sleep induced increase in upper airway resistance is a causal factor in the development of hypertension, nasal continuous positive airway pressure (CPAP) should have a beneficial effect on daytime hypertension in these patients. Although there are reports of successful closure of tracheostomy or discontinuation of nasal CPAP after weight loss,'5-18 a reduction in body weight usually has less impressive effects on OSA,'8-21 but weight loss is an effective treatment for hypertension. 22 The aim of this study was therefore to compare the relative contributions of long term nasal CPAP and weight loss on the course of hypertension in patients with OSA.
Methods
Seventy three consecutive patients with sleep apnoea and a history of hypertension who had been receiving antihypertensive drugs for at least five years were included in the study. All had an apnoea hypopnoea index (AHI) above 10 (12.6-90) and were offered treatment with nasal CPAP. Thirty nine patients accepted nasal CPAP as home therapy, but the other 34 patients refused both nasal CPAP and upper airway surgery so a recommendation of weight loss was the only therapeutic intervention.
Diagnosis Measurements were made on both arms in the supine position and the highest value was used for statistical analysis. For the two months before each PSG night, at least two blood pressure readings were available from the patients' general practitioners. These values were also entered into the analysis. Baseline and follow up systolic, mean and diastolic blood pressures were therefore calculated as the means of the laboratory and the general practitioners' readings.
All the patients were on antihypertensive medication. Those nine patients (two from the nasal CPAP group and seven from the non-compliant group) in whom a drug taken at the time of the baseline investigation had been replaced by an alternative drug until follow up were excluded from the analysis. If there was a reduction in the prescribed daily dose of an antihypertensive drug taken at baseline, or if this drug had been omitted until follow up, this was regarded as an improvement of hypertension. By analogy, initiation of an additional antihypertensive drug as well as an increase in the prescribed daily dose was defined as a worsening of hypertension. If the dose of drugs had not been changed since the baseline investigation, a decrease or increase in mean blood pressure of at least 10 mm Hg, or more than 8%, was defined as a significant change in hypertension.
At follow up, compliance with nasal CPAP was checked by readings of the built in time counter of the patient's device (Sleep Easy II or III, Respironics, Monroeville, Pennsylvania, USA). Only those patients for whom calculation of the time of use per night (hours of operation divided by days since prescription) gave a value higher than four hours were considered compliant with nasal CPAP. A further four patients therefore had to be excluded.
With this method of patient selection there were 33 patients with OSA who were highly compliant with nasal CPAP therapy, indicated by a time of use of 5-7 (0-2) hours per night, and 27 patients who received no treatment for OSA except the recommendation of weight loss. As only some of the patients 108 (2 4 
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The one way ANOVA suggested that ini-S s tial blood pressure, nasal CPAP use, and 005 changes in BMI contributed significantly to hypo changes in blood pressure in patients compliant with nasal CPAP. In refusers of nasal CPAP only changes in BMI were found to relate to changes in hypertension (table 4) . There was, however, a significant correlation between the change in BMI and the change in AHI in refusers of nasal CPAP (r = 049; p < 0 05). In the nasal CPAP group the influences of nasal CPAP use, as well as of initial blood pressure, disappeared when all the variables were entered into a multivariate + ANOVA with hypertension (improved, unchanged, or worse) as the dependent variable, and only the percentage change in BMI predicted a change in hypertension (F ratio = 13-1; p < 0-0001). The same result was found for refusers of nasal CPAP (F ratio = 7-6; p < 0 005). In contrast, in the group that lost weight, initial AHI contributed to the outcome of hypertension, but as in the group that did not lose weight, nasal CPAP did not.
For the study population as a whole, again only the percentage change in BMI contributed significantly to the outcome of hypertension at follow up (F ratio = 11A4; p < 0o00O1). Generally a change in insulin metabolism is thought to be responsible for the association between obesity and hypertension,2829 but the effect of obesity on the upper airway may be equally important. Obesity, by causing pharyngeal fat deposition, can increase upper airway resistance which predisposes to snoring and episodes of apnoea during sleep.30 By disturbing sleep architecture, even snoring without apnoeic episodes may cause daytime sleepiness3' which, in tum, favours weight gain due to lack of physical activity during the day. This further increase in body weight may worsen upper airway resistance, so that a vicious cycle develops. Assuming that sleep fragmentation resulting from snoring or apnoeic episodes is associated with increased sympathetic activity, this may enhance the development of hypertension. In a recent study32 we found elevated but nearly identical prevalences of hypertension in snorers with and without sleep apnoea, suggesting that an obesity induced increase in upper airway resistance even in the absence of OSA may be a risk factor for hypertension.
If increased upper airway resistance during sleep actually contributes to elevated daytime blood pressure, one would expect that nasal CPAP invariably has a beneficial effect on hypertension, but this occurred in less than one third of our patients. Those patients whose hypertension did not improve, however, were obese and had suffered from hypertension for many years, so that structural vascular changes or an obesity related mechanism that does not involve upper airway resistance might have been responsible for the failure of nasal CPAP to reduce daytime blood pressure. The same explanation may be true for refusers of nasal CPAP whose hypertension remained unchanged despite significant weight loss.
As we considered it unethical to recommend weight loss only to refusers of nasal CPAP, weight loss in the group receiving nasal CPAP may have been a confounding factor. If nasal CPAP alone had a beneficial effect on the course of hypertension, however, weight loss in patients receiving nasal CPAP should have enhanced this effect leading to more patients with an improvement of hypertension at follow up in this group compared with the group who refused nasal CPAP. On the other hand, acceptors of nasal CPAP had more severe OSA than refusers. Assuming a gradual increase in AHI with the time OSA persists, one might hypothesise that, if hypertension parallels OSA, elevated blood pressure also persisted for a longer period of time than in the group who refused CPAP, so reversibility could have been poorer.
Obviously there are some methodological problems that have to be taken into account in interpreting our results. Firstly, all our patients were on antihypertensive drugs so that use of absolute blood pressure values was limited. We therefore had to find a limit for a significant change in measured blood pressure from baseline to follow up which was totally arbitrary. Since lowering the prescribed dose of drugs reflects better control of the hypertensive condition, it appears reasonable also to define a change in the prescribed dose of medication as a response. Secondly, we were unable to monitor compliance with antihypertensive medication so that our results are based solely on prescribed medication. As our patients were on antihypertensive drugs for more than five years, it is unlikely that a relevant change in their compliance with antihypertensive treatment occurred during the study period that could have biased our results. Finally, as blood pressure measurements in the sleep laboratory only provide single points that may not reflect the actual blood pressure during the rest of the day, we tried to minimise this problem by including blood pressure readings by the patients' general practitioners during the two months preceding each sleep study, accepting by this that blood pressure was measured by different subjects with different devices at different times of the day.
In conclusion, the main finding of this study was that the course of hypertension in OSA is more closely linked to changes in body weight than to elimination of apnoeic episodes during sleep by nasal CPAP. Even in those who refused nasal CPAP who lost weight, we failed to find an independent effect of a change in severity of OSA on the course of hypertension. Our findings do not, however, preclude that a reduction in upper airway resistance during sleep either by nasal CPAP or by increasing pharyngeal cross sectional area due to weight loss might have been the common underlying mechanism for the changes in blood pressure observed.
